Treatment Information

Back

Colon Cancer treatment details. Chemotherapy, Biologic therapy.

Institut Gustave Roussy, Villejuif Cedex, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Villejuif Cedex
Treatments:Chemotherapy, Biologic therapyHospital:Institut Gustave Roussy
Drugs:Journal:Link
Date:Apr 2013

Description:

Patients:
This phase 2 study involved metastatic colorectal cancer patients who were separated into two different treatment groups. Group A consisted of 72 patients with a median age of 61 years and 64% were male. Group B had 73 patients with a median age of 61 years and 48% were male.

Treatment:
Patients in group A were given the biologic therapy agent bevacizumab and the chemotherapy agents irinotecan and capecitabine.

Patients in group B were treated with the biologic therapy agent bevacizumab and a chemotherapy regimen consisting of 5-fluorouracil, leucovorin, and irinotecan.

Toxicities:
The most severe toxicities in group A were grade 4 neutropenia, blood clotting, and diarrhea. Grade 3 fatigue and vomiting were also reported.

The most severe toxicities in group B were grade 4 neutropenia, pulmonary embolism, and gastrointestinal perforation. Grade 3 fatigue, leucopenia, and vomiting were also reported.

Results:
The median overall survival was 23 months in both groups A and B.

Support:
This study was supported by the Roche, Pfizer, and Chugai pharmaceutical companies.

Correspondence: Dr. M. Ducreux; email: [email protected]



Back